|
1
|
Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds.
|
Assay Drug Dev Technol
|
2004
|
1.06
|
|
2
|
Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain.
|
J Med Chem
|
2011
|
0.85
|
|
3
|
PADLOC: a powerful tool to assign disulfide bond connectivities in peptides and proteins by NMR spectroscopy.
|
Anal Chem
|
2011
|
0.83
|
|
4
|
Engineering potent and selective analogues of GpTx-1, a tarantula venom peptide antagonist of the Na(V)1.7 sodium channel.
|
J Med Chem
|
2015
|
0.82
|
|
5
|
Discovery and hit-to-lead optimization of pyrrolopyrimidines as potent, state-dependent Na(v)1.7 antagonists.
|
Bioorg Med Chem Lett
|
2012
|
0.76
|
|
6
|
Discovery and optimization of aminopyrimidinones as potent and state-dependent Nav1.7 antagonists.
|
Bioorg Med Chem Lett
|
2011
|
0.76
|
|
7
|
Correction to "Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement".
|
ACS Med Chem Lett
|
2017
|
0.75
|
|
8
|
The discovery of aminopyrazines as novel, potent Na(v)1.7 antagonists: hit-to-lead identification and SAR.
|
Bioorg Med Chem Lett
|
2012
|
0.75
|